recombinant factor VIII N8

Known as: N8 rFVIII, N8 recombinant factor VIII 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2011
01219992011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Replacement therapy using recombinant factor VIII (rFVIII) is currently the most common therapy for hemophilia A, a bleeding… (More)
Is this relevant?
Review
2007
Review
2007
This retrospective survey of haemophilia A patients from multiple treatment centres in Ireland assessed the development of… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
2006
2006
Prophylactic treatment for hemophilia A involves infusion of factor VIII (FVIII) concentrates every 2 to 3 days. Liposomes can be… (More)
Is this relevant?
2006
2006
http://bloodjournal.hematologylibrary.org/content/108/12/3668.full.html Updated information and services can be found at: (2497… (More)
  • table 1
  • table 3
  • table 2
  • figure 1
  • table 4
Is this relevant?
2000
2000
Patients with cross-reacting material (CRM)-reduced haemophilia A exhibit reduced levels of factor VIII antigen. In this study… (More)
Is this relevant?
Review
1999
Review
1999
The development of inhibitors to factor VIII or IX is the most serious complication of haemophilia therapy. While early surveys… (More)
Is this relevant?